Evaluation of standard biomarkers (ER, PR, and HER2) in primary BC can be supplemented by molecular profiling with significant information on disease subtyping, which constitutes prognostic and predictive data that can help in treatment planning. This evidence concerns the gene ESR1 and breast cancer.